- Home
- HDL vs GYRE Comparison
HDL vs GYRE Comparison
Compare HDL & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HDL
- GYRE
- Stock Information
- Founded
- HDL 2016
- GYRE 2002
- Country
- HDL Singapore
- GYRE United States
- Employees
- HDL N/A
- GYRE N/A
- Industry
- HDL Restaurants
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- HDL Consumer Discretionary
- GYRE Health Care
- Exchange
- HDL Nasdaq
- GYRE Nasdaq
- Market Cap
- HDL 1.2B
- GYRE 897.1M
- IPO Year
- HDL 2024
- GYRE N/A
- Fundamental
- Price
- HDL $19.01
- GYRE $7.20
- Analyst Decision
- HDL
- GYRE
- Analyst Count
- HDL 0
- GYRE 0
- Target Price
- HDL N/A
- GYRE N/A
- AVG Volume (30 Days)
- HDL 3.2K
- GYRE 178.6K
- Earning Date
- HDL 08-26-2025
- GYRE 08-12-2025
- Dividend Yield
- HDL N/A
- GYRE N/A
- EPS Growth
- HDL 110.82
- GYRE N/A
- EPS
- HDL 0.06
- GYRE 0.02
- Revenue
- HDL $789,766,000.00
- GYRE $100,643,000.00
- Revenue This Year
- HDL $17.95
- GYRE $21.04
- Revenue Next Year
- HDL $13.32
- GYRE $89.64
- P/E Ratio
- HDL $305.69
- GYRE $89.89
- Revenue Growth
- HDL 10.91
- GYRE N/A
- 52 Week Low
- HDL $13.94
- GYRE $6.11
- 52 Week High
- HDL $30.00
- GYRE $19.00
- Technical
- Relative Strength Index (RSI)
- HDL N/A
- GYRE 44.34
- Support Level
- HDL N/A
- GYRE $7.37
- Resistance Level
- HDL N/A
- GYRE $7.80
- Average True Range (ATR)
- HDL 0.00
- GYRE 0.44
- MACD
- HDL 0.00
- GYRE 0.05
- Stochastic Oscillator
- HDL 0.00
- GYRE 49.43
About HDL SUPER HI INTERNATIONAL HOLDING LTD. American Depositary Shares
Super Hi International Holding Ltd is an investment holding company and its subsidiaries are principally engaged in restaurant operations, delivery business, and sales of hot pot condiment products and food ingredients located in the overseas market outside Mainland China, Hong Kong, Macau, and Taiwan. It mission is to become a global integrated restaurant group, build the world's Chinese cuisine brand, and promote Chinese culinary heritage world-wide.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.